<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="13538"><DrugName>Vasoflux</DrugName><DrugNamesKey><Name id="42750457">Vasoflux</Name></DrugNamesKey><DrugSynonyms><Name><Value>Vasoflux</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15964">Vascular Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="15964">Vascular Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="13538" type="Drug"><TargetEntity id="256550" type="siDrug">Vasoflux</TargetEntity></SourceEntity><SourceEntity id="15964" type="Company"><TargetEntity id="4296216992" type="organizationId">Vascular Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1076" type="ciIndication"><TargetEntity id="10043607" type="MEDDRA"></TargetEntity><TargetEntity id="D013927" type="MeSH"></TargetEntity><TargetEntity id="304" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="224" type="ciIndication"><TargetEntity id="10028596" type="MEDDRA"></TargetEntity><TargetEntity id="D009203" type="MeSH"></TargetEntity><TargetEntity id="-998451372" type="omicsDisease"></TargetEntity><TargetEntity id="226" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="111" type="Action"><TargetEntity id="502" type="Mechanism">Thrombin Inhibitors</TargetEntity><TargetEntity id="4384" type="Mechanism">Anti-Thrombin</TargetEntity></SourceEntity><SourceEntity id="659" type="Action"><TargetEntity id="3176" type="Mechanism">Inhibitors of Blood Coagulation Pathways</TargetEntity></SourceEntity><SourceEntity id="PTGT-00713" type="ciTarget"><TargetEntity id="161932276721473" type="siTarget">Prothrombin</TargetEntity><TargetEntity id="1159" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1076">Thrombosis</Indication><Indication id="224">Myocardial infarction</Indication></IndicationsSecondary><ActionsPrimary><Action id="111">Factor IIa antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="659">Coagulation inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>B1E</Code><Name>DIRECT THROMBIN INHIBITORS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-19T05:58:58.000Z</LastModificationDate><ChangeDateLast>2011-03-18T07:32:45.000Z</ChangeDateLast><AddedDate>1996-10-07T10:35:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Vascular Therapeutics has discontinued development of &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt;, a thrombin inhibitor, for the potential treatment of thrombotic conditions associated with acute myocardial infarction (AMI) [&lt;ulink linkID="311035" linkType="reference"&gt;311035&lt;/ulink&gt;]. The compound had reached multicenter phase II trials in AMI patients, but it did not achieve its predetermined endpoint [&lt;ulink linkID="317455" linkType="reference"&gt;317455&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The first phase II study was designed to determine the optimal dose of &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt; when used in conjunction with clot-dissolving drugs. The study enrolled approximately 300 patients in over 30 centers in the US, Canada, the Netherlands and New Zealand [&lt;ulink linkID="272420" linkType="reference"&gt;272420&lt;/ulink&gt;]. The double-blind study evaluated four dose levels of the drug versus placebo, administered in combination with streptokinase as a 60-minute infusion. The company expected to follow this trial with a similar protocol utilizing tissue plasminogen activator with a view to launching a phase III study with all three drugs [&lt;ulink linkID="273331" linkType="reference"&gt;273331&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 1997, the company announced completion of phase I trials where escalating doses of &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt; were evaluated, both alone and in combination with heparin, in 40 subjects who were monitored for four weeks. No significant adverse events were observed, even at the highest doses of &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt; and heparin. The highest dose administered was above the range shown to be efficacious in preclinical studies [&lt;ulink linkID="243583" linkType="reference"&gt;243583&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt; is a chemically and physically modified oligosaccharide that catalyzes a naturally occurring protein, which in turn inhibits clot-bound thrombin [&lt;ulink linkID="220129" linkType="reference"&gt;220129&lt;/ulink&gt;]. Pharmokinetic data developed from analysis of the subjects' blood-clotting markers confirmed the mechanism of action of &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt; [&lt;ulink linkID="243583" linkType="reference"&gt;243583&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt; was discovered as a result of basic research performed in conjunction with the Hamilton Civic Hospitals Research Center [&lt;ulink linkID="272420" linkType="reference"&gt;272420&lt;/ulink&gt;] &lt;/para&gt;&lt;para&gt;Vascular Therapeutics was awarded (July 1998) three patents for &lt;ulink linkID="13538" linkType="Drug"&gt;Vasoflux&lt;/ulink&gt; (US-05744457, US-05763427 and US-05767269) covering composition of matter, use and process of manufacture [&lt;ulink linkID="291770" linkType="reference"&gt;291770&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15964">Vascular Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>1999-01-08T00:00:00.000Z</StatusDate><Source id="311035" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15964">Vascular Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1076">Thrombosis</Indication><StatusDate>1999-01-08T00:00:00.000Z</StatusDate><Source id="311035" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15964">Vascular Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>1999-01-08T00:00:00.000Z</StatusDate><Source id="311035" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15964">Vascular Therapeutics Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>1999-01-08T00:00:00.000Z</StatusDate><Source id="311035" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15964">Vascular Therapeutics Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>1999-01-08T00:00:00.000Z</StatusDate><Source id="311035" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15964">Vascular Therapeutics Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>1998-01-06T00:00:00.000Z</StatusDate><Source id="273331" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15964">Vascular Therapeutics Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>1998-01-06T00:00:00.000Z</StatusDate><Source id="273331" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15964">Vascular Therapeutics Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>1998-01-06T00:00:00.000Z</StatusDate><Source id="273331" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15964">Vascular Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate>1997-12-16T00:00:00.000Z</StatusDate><Source id="272420" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15964">Vascular Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="224">Myocardial infarction</Indication><StatusDate>1997-12-16T00:00:00.000Z</StatusDate><Source id="272420" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15964">Vascular Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate>1997-04-25T00:00:00.000Z</StatusDate><Source id="243583" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15964">Vascular Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate>1996-10-07T10:35:10.000Z</StatusDate><Source id="220129" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00713"><Name>Factor IIa</Name><SwissprotNumbers><Swissprot>P00734</Swissprot><Swissprot>P00735</Swissprot><Swissprot>P18292</Swissprot><Swissprot>P19221</Swissprot><Swissprot>P84122</Swissprot><Swissprot>Q5R537</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="866889" number="WO-00102443" title="Heparin compositions that inhibit clot associated coagulation factors"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hamilton Civic Hospitals Research Development Inc" id="21889"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>